|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Exploring Novel Treatments for Rett Syndrome
STATEMENT OF NEED
Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including seizures, autistic features, autonomic nervous system dysfunction, breathing abnormalities, sleep dist... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
Operation Game- A Patient’s Journey Through HeFH: Diagnosis and Management
Target Audience
This activity has been designed to address the educational needs of cardiologists, cardiology nurses, lipid specialists, and primary care clinicians, including internists, pharmacists, nurses, nurse practitioners, PAs, and dietitians. It may also benefit other healthcare providers who manage patients with hypercholesterolemia.
Program Overview
Nonstatins are an essential therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels in high-risk patients, such as ... |
|
|
Advancing the Care of Patients Living with EGPA Through Multidisciplinary, Patient-Focused Care
Target Audience
This educational activity is intended for rheumatologists, allergists, immunologists, pulmonologists, and specialty advance practice clinicians who care for patients with EGPA.
Program Overview
The comprehensive program provides up-to-date information regarding EGPA"its recognition, diagnosis, and treatment"and incorporates the patient perspective to raise awareness of patients’ needs, heighten urgency, and, ultimately, educate on the disease. The program will ... |
|
|
Right Treatment, Right Patient: Evidence-Based Approaches to the Treatment of Moderate-to-Severe Atopic Dermatitis Snippet 1: Currently Available Injectable Biologic Therapies for Moderate-to-Severe Atopic Dermatitis (AD)
Target Audience
This activity is designed to meet the educational needs of dermatology and allergy physicians, nurse practitioners, PAs, and nurses who care for patients with moderate-to-severe atopic dermatitis.
Program Overview
This activity features a case presentation, a brief overview of currently available injectable biologic therapies, and insights from an expert faculty.
Learning Objectives
After completing this activity, the participant should be better able to::
Identify ... |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
May 16-18, 2024 Update CME Internal Medicine and Primary Care Conference
Eminent speakers from The University of Chicago, Northwestern University, The University of Illinois Chicago, and Rush University will provide comprehensive updates on the latest clinical guidelines.
Target Audience: Internal Medicine, Primary Care, Family Medicine, and Hospitalist Medicine Physicians, Nurse Practitioners, and Physician Assistants
Earn 25 CME Credits
This activity has been approved for AMA PRA Category 1 Credit™️.
This activity has been approved for AAFP Prescribe... |
|
|
The Role of the Clinical Pharmacist in the Management of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ... |
|
|
INFORM: Information Needed for Optimal Regulation of Mycophenolate- A REMS Activity
Target Audience
The target audience for this initiative includes obstetricians, gynecologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and care team members involved in the treatment of women across their reproductive lifespan who may have been prescribed mycophenolate products.
Program Overview
Clinicians who work with women of childbearing age who are, or will be, taking mycophenolate must ensure that their patients receive appropriate counseling... |
|
|
9th Annual Clinical Issues in Primary Care Conference
Presented by Continuing Education Company for over 30 years, our Primary Care CME Conference Series is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us in May 2024 for our 9th Annual Clinical Issues in Primary Care Conference at the Fairmont Orchid, Hawaii Resort on the Big Island
Program Objectives
As a result of this conference, participants will be able to:
Assess and p... |
|
|
Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood
Target Audience
The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians.
Program Overview
Join a panel of expert clinicians to identify the subtle and very early signs of DMD that may be detected before functional symptoms are noticed and that can help earlier diagnoses and appropriate interventions. Panelists will review the importance of matching mutations to therapeutic decisions, discuss emergin... |
|
|
Combining Locoregional and Systemic Therapy for Challenging HCC Cases
Target Audience
This educational activity is intended for interventional oncologyists physicians, nurses, and other members of the health care team who care for patients with hepatocellular carcinoma (HCC)
Program Overview
This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings.
Learning Objectives
Upon c... |
|
|
Eosinophilic Esophagitis: Experts Address Your Burning Questions
Eosinophilic esophagitis (EoE) is a chronic type 2 helper (Th2)-mediated inflammatory disorder that is characterized by symptoms of esophageal dysfunction and esophageal inflammation with intraepithelial eosinophils. Once considered rare, EoE is a relatively new disease that is now commonplace and affects both children and adults. When left unmanaged, EoE can impact a patient’s ability to eat properly, leading to food impaction and increased medical expenses. Recent data indicate that many c... |
|
|
Eyeing the Options for Treating Meibomian Gland Dysfunction and Dry Eye Disease
Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and subsequently undertreated. Studies have demonstrated that meibomian gland dysfunction (MGD) is a leading cause of the development and progression of evaporative DED, caused by a deficient tear film lipid layer that leads to increased tear evaporation. New and emerging treatments with novel mechanisms of action are being investigated that manage the signs and symptoms of DED associated with MGD and offer the potential f... |
|
|
Parenteral Nutrition Solutions: Developing a Playbook for the Multidisciplinary Team
In these symposium highlights, a multidisciplinary panel of experts discuss a range of topics, including the role of indirect calorimetry, protein requirements, intravenous lipid emulsions, and the nutrition support team. Also highlighted are a real-world patient case and the questions and answers/panel discussion. An accompanying infographic on the importance of the nutrition support team and how to organize one can be downloaded and shared with your team. |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing ... |
|
|
Sports Medicine 2024 -LIVE STREAMING
The Comprehensive 2024 Sports Medicine Update
State-of-the-Art Approaches to the Diagnosis, Treatment, Rehabilitation, and Prevention of Sports Injuries
This Harvard Medical School CME program, which is among the highest-rated HMS CME courses, provides a special and timely opportunity to hear directly from world-renowned physician specialists (physiatrists, orthopedists, radiologists), team physicians and athletic trainers for the Boston Red Sox, New England Revolution, and New England P... |
|
|
WEBINAR: Metronomic Chemotherapy: Hope vs. Hype
Metronomic chemotherapy has become quite popular with oncologists and general practitioners. There are some basic scientific data addressing its mechanism of action, however, the vast amount of data is purely retrospective in nature. These studies vary in drug dosage and protocols used making assessment between studies challenging. On top of this, there are no good surrogate markers for efficacy to help guide clinicians. Last, the use of metronomic therapy has opened our eyes to the challenges... |
|
|
Ulcerative Colitis and the Role of S1P Receptor Modulators and JAK Inhibitors " A Wheel of Knowledge Challenge!
Ulcerative colitis (UC), a type of inflammatory bowel disease, is a chronic relapsing condition characterized by an overly active immune response in the large intestine, resulting in inflammation and ulceration. Given the increasing prevalence of disease and rapid influx of available biologics and small molecule therapies, there is great need for ongoing education regarding new and emerging treatment approaches for the management of UC. In this continuing education program, expert clinicians w... |
|
|
Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest... |
|
|
Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes
Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ... |
|
|
State-of-the-Art Obesity Management in the Primary Care Setting
Access our robust online slide library covering the management of obesity in the primary care setting. Expert faculty in weight management developed content related to epidemiology, pathophysiology, and complications of obesity; screening and diagnosis; patient counseling; case studies; nonpharmacologic therapies; and pharmacologic therapies. Choose your topic interests and customize your own slide deck to broaden your knowledge and improve the care and outcomes of patients with obesity.
Ob... |
|
|
28th Annual Hypertension, Diabetes & Dyslipidemia Conference
This three day intensive conference, held on June 19-21, 2024 in Charleston, South Carolina, addresses all the issues confronting clinicians who treat challenging patients with diabetes, hypertension, and dyslipidemia and how to apply this knowledge to everyday practice.
Over the past several years controversies in the appropriate target for Hemoglobin A1C, BP, and LDL-Cholesterol on outcome improvement continue to occur in Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Desp... |
|
|
32nd Annual Primary Care Conference, Session 1
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
|
Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ... |
|
|
Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a... |
|
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
|
Gastroenterology 2024 - LIVE STREAMING
The Comprehensive 2024 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2024 program include:
• Updated... |
|
|
Treating Obesity 2024: The Blackburn Course in Obesity Medicine - LIVE STREAMING
Education to Optimize Your Care of Adult, Adolescent, and Pediatric Patients with Obesity
This highly rated Harvard Medical School CME course delivers practical strategies to optimize the management of obesity and its many complications, and provides the most up-to-date approaches to obesity prevention and treatment.
Highlights of the 2024 program include:
• Update on using the newer GLP-1 based therapies
• Comprehensive evaluation of the patient with obesity
• Emerging precision me... |
|
|
Emerging Therapies, Novel Mechanisms, and New Hope in the Treatment of PAH
The treatment landscape of pulmonary arterial hypertension (PAH) is poised to change dramatically in the near future. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for all practicing pulmonology and cardiology learners. What are some of the emerging therapies for PAH, and how do they differ from current treatment options? Which emerging therapies may be disease modifying? What clinical trial evidence is there for the treatments being inve... |
|
|
Lifestyle Medicine: Tools for Promoting Healthy Change - LIVE STREAMING
State-of-the-Art Approaches to Help Patients Initiate and Sustain Health-Promoting Behaviors
Lifestyle Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.
Overview
This immersive two-day course offers state-of-the-art strategies to guide patients to healthier lives. Education includes evidence-based strategies, tools and techniques to effect healthier changes in patients (and ourselves), including weight loss, exerci... |
|
|
June 27-29, 2024 Update CME Internal Medicine and Primary Care Conference
Eminent speakers from The University of Chicago, Northwestern University, The University of Illinois Chicago, and Rush University will provide comprehensive updates on the latest clinical guidelines.
Target Audience: Internal Medicine, Primary Care, Family Medicine, and Hospitalist Medicine Physicians, Nurse Practitioners, and Physician Assistants
Earn 25 CME Credits
This activity has been approved for AMA PRA Category 1 Credit™️.
This activity has been approved for AAFP Prescribe... |
|
|
32nd Annual Primary Care Conference, Session 2
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
|
15th Annual Essentials in Primary Care Summer Conference
Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The Essentials in Primary Care Summer Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this July when we hold the 15th Annual Essentials in Primary Care Summer Conference.
This conference will be held at the Hammock Beach Resort in Palm Coast, Florida. Located n... |
|
|
Right Treatment, Right Patient: Evidence-Based Approaches to the Treatment of Moderate-to-Severe Atopic Dermatitis Snippet 2: Currently Available Oral Therapies for Moderate-to-Severe Atopic Dermatiti
Target Audience
This activity is designed to meet the educational needs of dermatology and allergy physicians, nurse practitioners, PAs, and nurses who care for patients with moderate-to-severe atopic dermatitis.
Program Overview
This activity features a case presentation, a brief overview of currently available oral therapies, and insights from expert faculty.
Learning Objectives
After completing this activity, the participant should be better able to::
Identify the biologic prope... |
|
|
Reducing Risks in Asthma: Mucus Plugs and Airway Obstruction
Target Audience
The educational design of this activity addresses the needs of pulmonology and clinical immunology clinicians who manage patients with severe asthma who are at risk for mucus plugs.
Program Overview
This Point-of-Care 201 program has been designed to educate and promote critical thinking through a discussion-based format that is accompanied by 3-dimensional animation. Expert faculty examine various sides of key clinical issues in asthma"including exploration of the pa... |
|
|
Making the Call in Nonadvanced Systemic Mastocytosis Optimizing Multidisciplinary Management
Series Overview
Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the... |
|